[Skip to Navigation]
Comment & Response
April 17, 2019

Learning About Dupilumab-Associated Conjunctivitis—Reply

Author Affiliations
  • 1Department of Dermatology, Feinberg School of Medicine, Northwestern, University, Chicago, Illinois
  • 2Kraff Eye Institute, Chicago, Illinois
JAMA Dermatol. 2019;155(6):754-755. doi:10.1001/jamadermatol.2019.0209

In Reply We are grateful to Hendricks and Shi for their interest in our recent article.1 We wholeheartedly agree that the difference in adverse events between those treated for AD vs asthma is striking and warrants deeper investigation. The suggestions that they have offered are insightful and compelling; however, we can address 2 of their specific points about possible underlying keratoconus or allergic conjunctivitis: (1) one of us (C.K.-C.), an ophthalmologist, noted that while formal corneal mapping was not performed, none of the patients appeared to present clinically with keratoconus; (2) all of the patients in our study denied a history of symptoms suggestive of allergic conjunctivitis when asked.

Add or change institution